External open innovation partner programNovel complement-based inhibitory peptides for the treatment of rare diseases
Part of the innate immune defense, the complement system plays a significant role in human physiology and disease, not only confined to the elimination of infectious pathogens and immune complexes. Complement is normally carefully regulated so it targets only unwanted materials and does not attack the body’s healthy cells. However, excessive or dysregulated complement activation contributes to many inflammatory, autoimmune and degenerative diseases.
We are looking for peptides that inhibit complement activation in orphan or rare diseases or niche indication.
All proposals will be assessed by our Research & Development team. Based on the level of interest within our research portfolio and the strategic fit of the proposals into Zealand Pharma long-term research focus, we will enter into discussion with selected candidate(s), potentially leading to funding and partnership agreements.
Proponents that submit proposals of interest will be contacted within 6 weeks of submission to clarify additional details concerning the underlying science as well as intellectual property rights, timelines, etc
Submit your proposal online (it takes about 15 minutes) in a form and length that is sufficient to provide the substance of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project and how that knowledge could be supplemented (i.e., what is additionally required to complete the project).
While Zealand Pharma will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.
If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
Zealand Pharma A/S (110 employees, based in Copenhagen) is a biotech company with leading-edge scientific expertise in turning peptides into revolutionary medicines that improve people’s lives. This mission is achieved through internal innovation, and collaboration with leading healthcare companies, academic institutions and biotechnology companies.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 8 main types of partnering programs with Academia.